Market Overview

MediciNova (NASDAQ:MNOV) Press Releases

Monday, October 07, 2019

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan (MNOV, Press Releases / Mon, 07:00pm)

Monday, September 30, 2019

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China (MNOV, News, Health Care, Legal, Press Releases / Mon, 07:00pm)

Wednesday, September 11, 2019

MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York (MNOV, News, Press Releases / Wed, 07:00pm)

Thursday, August 29, 2019

MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York (MNOV, News, Press Releases / Thu, 07:00pm)

Tuesday, July 30, 2019

MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan (MNOV, Press Releases, General / Tue, 07:00pm)

Monday, July 29, 2019

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia (MNOV, News, Health Care, Press Releases / Mon, 07:00pm)

Wednesday, July 24, 2019

MediciNova Appoints Kazuko Matsuda to its Board of Directors (MNOV, News, Management, Press Releases / Wed, 11:00pm)

Thursday, July 11, 2019

MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS (MNOV, Health Care, Press Releases / Thu, 07:00pm)

Wednesday, June 12, 2019

MediciNova to Present at the JMP Securities Life Sciences Conference (MNOV, News, Press Releases / Wed, 07:00pm)

Wednesday, June 05, 2019

MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS (MNOV, Health Care, Press Releases, General / Wed, 07:00pm)

Thursday, May 16, 2019

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of MediciNova, Inc. (MNOV, News, Legal, Press Releases / Thu, 01:14pm)

Wednesday, May 15, 2019

MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference (MNOV, News, Press Releases / Wed, 07:00pm)

Tuesday, May 07, 2019

MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom (MNOV, Press Releases / Tue, 07:00pm)

Tuesday, April 23, 2019

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma (MNOV, Health Care, Press Releases / Tue, 07:00pm)

Monday, April 15, 2019

MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS (MNOV, Health Care, Press Releases, General / Mon, 07:00pm)

Wednesday, April 03, 2019

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China (MNOV, News, Legal, Press Releases / Wed, 07:00pm)

Monday, April 01, 2019

MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS (MNOV, Press Releases / Mon, 07:00pm)

Sunday, March 24, 2019

MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania (MNOV, News, Press Releases, General / Sun, 07:00pm)

Tuesday, March 05, 2019

MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan (MNOV, Press Releases / Tue, 07:51pm)

Thursday, February 28, 2019

MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports (MNOV, Press Releases / Thu, 07:00pm)

Monday, January 21, 2019

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases (MNOV, News, Legal, Press Releases / Mon, 07:00pm)

Tuesday, January 08, 2019

MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma (MNOV, Health Care, Press Releases / Tue, 07:00pm)

Monday, January 07, 2019

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan (MNOV, News, Legal, Press Releases, General / Mon, 07:00pm)

Wednesday, December 12, 2018

MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco (MNOV, Press Releases / Wed, 07:00am)

Thursday, October 04, 2018

MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma (MNOV, Press Releases / Thu, 07:00pm)

Tuesday, September 25, 2018

MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS (MNOV, Health Care, Press Releases / Tue, 07:00pm)

Tuesday, September 18, 2018

MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York (MNOV, News, Press Releases / Tue, 07:00pm)

Tuesday, September 04, 2018

MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York (MNOV, News, Press Releases / Tue, 07:00pm)

Wednesday, August 29, 2018

MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine (MNOV, Health Care, Press Releases / Wed, 05:00pm)

Monday, August 20, 2018

Monday, August 06, 2018

MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge (MNOV, Press Releases, General / Mon, 07:00pm)

Tuesday, July 31, 2018

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK (MNOV, News, Press Releases / Tue, 07:00pm)

Sunday, July 29, 2018

MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial (MNOV, Press Releases / Sun, 07:00pm)

Wednesday, July 11, 2018

Drug Developers Expecting Significant Clinical and Economic Benefits by Targeting Newest Drug Therapies (BCRX, CELG, MBRX, MNOV, XLRN, Retail Sales, Small Cap, Opinion, Press Releases / Wed, 08:15am)

Monday, July 09, 2018

MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS (MNOV, Health Care, Press Releases / Mon, 07:00pm)

1	TLRY, RBS: 26 Stocks Moving in Thursday's Pre-Market Session
2	IPHI, SNBR: 23 Stocks Moving in Wednesday's Pre-Market Session
3	CTST, ACB: Cronos Group's 40% After-Hours Mystery Rally: W...
4	AA, RLI: Earnings Scheduled For October 16, 2019
5	ETFC, OZK: Earnings Scheduled For October 17, 2019
6	ISRG, IBM: 10 Stocks To Watch For Octo...
7	IP, CRON: Najarian Brothers H...

1	FreightWaves LIVE Chicago: Fireside Chats Offer Deep Dives Into Future Of Transp...
2	MRTN: Marten Transport Posts Best-Ever Operating Revenue, Income In Third Quarter
3	4 Cannabis Podcasts You Should Be Listening To Right Now
4	Eating Disorder? Cannabis May Help
5	GlobalTranz Acquires Chicago-Based Brokerage Global Freight Solutions
6	Gecas Places Freighters With Struggling Garuda
7	ISRG, OFLX: 4 Stocks Moving In Thursday's After-Hours Session

Book A Demo

Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo